Edwards Lifesciences Corporation
EW
$85.98
-$1.56-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.15% | 11.55% | 10.60% | 9.14% | 8.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.15% | 11.55% | 10.60% | 9.14% | 8.23% |
| Cost of Revenue | 23.23% | 19.39% | 19.24% | 12.89% | 10.32% |
| Gross Profit | 11.80% | 9.52% | 8.40% | 8.18% | 7.71% |
| SG&A Expenses | 17.20% | 16.49% | 15.23% | 12.38% | 12.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -221.13% | -22,300.00% | 50.78% | 76.88% | 47.57% |
| Total Operating Expenses | 14.32% | 11.90% | 16.52% | 14.59% | 10.77% |
| Operating Income | 13.70% | 10.62% | -2.46% | -2.78% | 2.15% |
| Income Before Tax | -19.42% | -17.78% | 3.11% | 7.75% | 15.38% |
| Income Tax Expenses | 27.71% | 42.60% | 67.12% | 43.96% | 14.80% |
| Earnings from Continuing Operations | -25.20% | -24.36% | -3.42% | 3.66% | 15.45% |
| Earnings from Discontinued Operations | -99.25% | -99.52% | -99.07% | 2,331.11% | 1,539.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -55.36% | -16.33% | 42.11% | 66.67% | 43.59% |
| Net Income | -73.78% | -74.28% | -67.11% | 181.58% | 195.71% |
| EBIT | 13.70% | 10.62% | -2.46% | -2.78% | 2.15% |
| EBITDA | 13.72% | 10.51% | -1.20% | -3.21% | 1.54% |
| EPS Basic | -73.20% | -73.78% | -66.47% | 185.96% | 200.24% |
| Normalized Basic EPS | 18.23% | 11.48% | -4.01% | -0.97% | 6.57% |
| EPS Diluted | -73.34% | -73.95% | -66.58% | 186.40% | 200.96% |
| Normalized Diluted EPS | 18.21% | 11.58% | -3.86% | -0.75% | 6.78% |
| Average Basic Shares Outstanding | -1.88% | -2.16% | -2.40% | -2.28% | -1.85% |
| Average Diluted Shares Outstanding | -1.87% | -2.24% | -2.55% | -2.50% | -2.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |